(Reuters) - Celgene Corp said it would allow the sale of a generic version of its flagship multiple myeloma drug, Revlimid, in the United States more than a year before the drug's patent expires.
The company said it would allow India-based Natco Pharma Ltd and its U.S. partner to market an unlimited quantity of generic Revlimid beginning Jan. 31, 2026 as part of a patent litigation settlement.
Patents covering Revlimid expire in April 2027.
The sale is subject to Natco securing U.S. Food and Drug Administration approval to market the copycat version.
Natco will also receive a "volume-limited" licence to sell in the United States commencing in March 2022, Celgene said.
(Reporting by Natalie Grover in Bengaluru; Editing by Sriraj Kalluvila)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app